Clinical and Pathological Features of the 140 Analyzed Cases With HD
| Gender | ||
| Male | 93 | (66.43%) |
| Female | 47 | (33.57%) |
| Age (yr) | ||
| Range | 5-83 | |
| Mean ± SD | 37.2 ± 17.5 | |
| <61 | 115 | (83.67%) |
| >60 | 24 | (16.43%) |
| B symptoms | ||
| Present | 76 | (54.29%) |
| Absent | 64 | (45.71%) |
| Stage (Ann Arbor) | ||
| I | 24 | (17.14%) |
| II | 49 | (35.00%) |
| III | 39 | (27.83%) |
| IV | 28 | (20.00%) |
| Response to therapy and relapses | ||
| Complete remission | 111 | (79.29%) |
| Relapses | 20 | (18.02%) |
| Relapse free survival (mo) | ||
| Range | 5-75 | |
| Mean | 28 | |
| Relapses >2 yr from diagnosis | 12 | (60.00%) |
| Relapse free survival (mo) | ||
| Range | 5-24 | |
| Mean | 16 | |
| Treatment failure | 29 | (20.71%) |
| Actuarial status and overall survival | ||
| Alive | ||
| Cases | 98 | (70.00%) |
| Overall survival (mo) | ||
| Range | 24-144 | |
| Mean | 65 | |
| Deaths | ||
| Cases | 28 | (20.00%) |
| Overall survival (mo) | ||
| Range | 0-102 | |
| Mean | 25 | |
| Missing cases | 14 | (10.00%) |
| All | ||
| Cases | 140 | (20.00%) |
| Overall survival (mo) | ||
| Range | 0-144 | |
| Mean | 54 | |
| Histopathological type | ||
| Lymphocytic predominance | 13 | (09.29%) |
| Nodular sclerosis | 74 | (52.86%) |
| Mixed cellularity | 49 | (35.00%) |
| Lymphocytic depletion | 4 | (02.86%) |
| Gender | ||
| Male | 93 | (66.43%) |
| Female | 47 | (33.57%) |
| Age (yr) | ||
| Range | 5-83 | |
| Mean ± SD | 37.2 ± 17.5 | |
| <61 | 115 | (83.67%) |
| >60 | 24 | (16.43%) |
| B symptoms | ||
| Present | 76 | (54.29%) |
| Absent | 64 | (45.71%) |
| Stage (Ann Arbor) | ||
| I | 24 | (17.14%) |
| II | 49 | (35.00%) |
| III | 39 | (27.83%) |
| IV | 28 | (20.00%) |
| Response to therapy and relapses | ||
| Complete remission | 111 | (79.29%) |
| Relapses | 20 | (18.02%) |
| Relapse free survival (mo) | ||
| Range | 5-75 | |
| Mean | 28 | |
| Relapses >2 yr from diagnosis | 12 | (60.00%) |
| Relapse free survival (mo) | ||
| Range | 5-24 | |
| Mean | 16 | |
| Treatment failure | 29 | (20.71%) |
| Actuarial status and overall survival | ||
| Alive | ||
| Cases | 98 | (70.00%) |
| Overall survival (mo) | ||
| Range | 24-144 | |
| Mean | 65 | |
| Deaths | ||
| Cases | 28 | (20.00%) |
| Overall survival (mo) | ||
| Range | 0-102 | |
| Mean | 25 | |
| Missing cases | 14 | (10.00%) |
| All | ||
| Cases | 140 | (20.00%) |
| Overall survival (mo) | ||
| Range | 0-144 | |
| Mean | 54 | |
| Histopathological type | ||
| Lymphocytic predominance | 13 | (09.29%) |
| Nodular sclerosis | 74 | (52.86%) |
| Mixed cellularity | 49 | (35.00%) |
| Lymphocytic depletion | 4 | (02.86%) |